Valentina Orlando, Damien Drubay, Pernelle Lavaud, Laura Faivre, François Lesaunier, Remy Delva, Gwenaëlle Gravis, Frédéric Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houede, Loic Mourey, Christine Theodore, Ivan Krakowski, Jean-François Berdah, Marjorie Baciuchka, Brigitte Laguerre, Aude Fléchon, Marine Grosse-Goupil, Isabelle Cojean-Zelek, Stéphane Oudard, Jean-Luc Labourey, Paule Chinet-Charrot, Eric Legouffe, Jean-Léon Lagrange, Claude Linassier, Gaël Deplanque, Philippe Beuzeboc, Jean-Louis Davin, Anne-Laure Martin, Meryem Brihoum, Stéphane Culine, Gwénaël Le Teuff, Karim Fizazi
INTRODUCTION: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases is not fully established. PATIENTS AND METHODS: Ancillary analysis from the GETUG 12 phase 3 trial. Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography (CT) scan were randomly assigned to receive androgen deprivation therapy (ADT) and docetaxel plus estramustine or ADT alone...
May 7, 2023: Clinical Genitourinary Cancer
Jiatong Zhou, Minghao Yu, Jie Ding, Jun Qi
OBJECTIVE: To determine the clinical significance of Gleason score(GS) 7 upgraded on radical prostatectomy(RP) and its impact on the prognosis of patients. PATIENTS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) database to study 8832 men diagnosed with M0 GS 3+4/4+3 prostate cancer (PCa) from 2010 to 2015 treated by RP. Logistic regression was used to analyze the effect of clinicopathological characteristics on the Gleason sore upgraded...
May 7, 2023: Clinical Genitourinary Cancer
Yasuyuki Kobayashi, Hiroki Arai, Yuichiro Hamamoto, Kyotaro Yoshida, Shigeki Shimizu, Yumiko Yasuhara, Naotsugu Ichimaru
OBJECTIVES: To investigate the prognostic value of CD68- and CD163-positive macrophages in patients with upper urinary tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: This retrospective study enrolled 50 patients (34 men and 16 women) with UTUC who received radical nephroureterectomy (RNU). We evaluated the expression of CD68 and CD163 in the intratumor compartment by immunohistochemistry. The Kaplan-Meier method and Cox proportional hazards regression model were used to evaluate overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and bladder recurrence-free survival (BRFS)...
May 7, 2023: Clinical Genitourinary Cancer
Hector Ayerra Perez, Javier Fermín Barba Abad, Javier Extramiana Cameno
Radical treatments and active surveillance are valid therapeutic approaches for low-risk prostate cancer. The oncologic effectiveness and morbidity of Radical Prostatectomy (RP) and radiotherapy have been broadly validated. Focal therapies pursue to reduce the morbidity observed after radical treatments, while preserving the oncologic effectiveness. This study aims to review the state-of-the-art about principles, oncologic effectiveness, morbidity, and side-effects associated with leading focal therapies. We review and summarize articles related with Cryotherapy, High-Intensity Focal Ultrasound (HIFU), Photodynamic Therapy (PDT), and Irreversible Electroporating (IRE) published in MEDLINE from 2000 to 2022...
May 3, 2023: Clinical Genitourinary Cancer
Umang Swami, Himani Aggarwal, Mo Zhou, Shan Jiang, Jeri Kim, Weiyan Li, François Laliberté, Bruno Emond, Neeraj Agarwal
BACKGROUND: Prostate cancer (PC) is more likely to develop in men ≥65 years old than in those <65 years old. This study aimed to generate real-world evidence on treatment patterns, clinical outcomes, health care resource utilization (HCRU), and costs among older patients with metastatic castration-resistant PC (mCRPC). MATERIALS AND METHODS: A claims algorithm based on treatments expected for mCRPC was used to identify men ≥65 years old with mCRPC in the SEER-Medicare data between 2007 and 2019...
May 3, 2023: Clinical Genitourinary Cancer
Tina Vaziri, Yuan J Rao, Michael Whalen, Jeffrey Bethony, Punam Thakkar, Jianqing Lin, Sharad Goyal
INTRODUCTION: We aimed to characterize the clinicopathological characteristics and outcomes of HIV-positive patients with clinically localized, prostate cancer (PCa). METHODS: A retrospective study was conducted of HIV-positive patients from a single institution with elevated PSA and diagnosis of PCa by biopsy. PCa features, HIV characteristics, treatment type, toxicities, and outcomes were analyzed by descriptive statistics. Kaplan-Meier analysis was used to determine progression-free survival (PFS)...
April 29, 2023: Clinical Genitourinary Cancer
Taisuke Tobe, Tomoaki Terakawa, Takuto Hara, Hideto Ueki, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Yuzo Nakano, Kenichi Harada, Masato Fujisawa
No abstract text is available yet for this article.
April 28, 2023: Clinical Genitourinary Cancer
Sanjay Das, Lin Gu, Claire Trustram Eve, Joshua Parrish, Amanda M De Hoedt, Chad McKee, William Aronson, Stephen J Freedland, Stephen B Williams
INTRODUCTION: Prior studies suggest that white light cystoscopy (WLC) alone can fail to detect cases of non-muscle invasive bladder cancer (NMIBC) vs. blue light cystoscopy (BLC). We describe bladder cancer outcomes and the impact of BLC among NMIBC patients in an equal access setting. MATERIALS AND METHODS: We assessed 378 NMIBC patients within the Veterans Affairs system that had a CPT code for BLC from December 1, 2014 to December 31, 2020. We determined recurrence rates and time to recurrence prior to BLC (ie, after previous WLC if available) and following BLC...
April 28, 2023: Clinical Genitourinary Cancer
Corbin J Eule, Junxiao Hu, Sulaiman Al-Saad, Katharine Collier, Patrick Boland, Akeem R Lewis, Rana R McKay, Vivek Narayan, Dominick Bosse, Amir Mortazavi, Tracy L Rose, Brian A Costello, Alan H Bryce, Elaine T Lam
BACKGROUND: De novo neuroendocrine prostate cancer (NEPC) and treatment-emergent neuroendocrine prostate cancer (T-NEPC) are rare diseases with a poor prognosis. After first-line platinum chemotherapy, there is no consensus on second-line treatments. PATIENTS AND METHODS: Patients with a pathologic diagnosis of de novo NEPC or T-NEPC between 2000 and 2020 who received first-line platinum and any second-line systemic therapy were selected and standardized clinical data was collected via the electronic health record at each institution...
April 24, 2023: Clinical Genitourinary Cancer
Judith Stangl-Kremser, Neal Patel, Jim C Hu
PURPOSE: Using nationally representative data, we determined the likelihood of adverse pathology at radical prostatectomy (RP) to better inform case selection for partial gland ablation (PGA). MATERIALS AND METHODS: We identified men with clinically localized GG2 (n = 106,048) and GG3 (n = 55,488) prostate cancer on biopsy from 2010 through 2019 who subsequently underwent RP. Men with GG2 were stratified as unfavorable and favorable per NCCN guidelines...
April 23, 2023: Clinical Genitourinary Cancer
Mary E Hall, Whitney J Padgett, Zachary Klaassen, Diana E Magee, Amy N Luckenbaugh, Aaron A Laviana, Raj Satkunasivam, Kerry Schaffer, Christopher J D Wallis
INTRODUCTION: While abiraterone acetate (AA) has demonstrated survival benefit in advanced prostate cancer (APC), meaningful cardiotoxicity is observed. It is unclear whether the magnitude differs based on disease indication and concurrent steroid administration. METHODS: We performed a systematic review and meta-analysis of phase II/III RCTs of AA in APC published as of August 11, 2020. Primary outcomes examined were all- and high-grade (grade ≥ 3) hypokalemia and fluid retention, and secondary outcomes included hypertension and cardiac events...
April 23, 2023: Clinical Genitourinary Cancer
Babette I Laarhuis, Marcel J R Janssen, Michiel Simons, Ludwike W M van Kalmthout, Maarten J van der Doelen, Steffie M B Peters, Harm Westdorp, Inge M van Oort, Geert Litjens, Martin Gotthardt, James Nagarajah, Niven Mehra, Bastiaan M Privé
INTRODUCTION: Prostate specific membrane antigen (PSMA) directed radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. However, it is still poorly understood why approximately 40% of the patients does not respond to PSMA-RLT. The aims of this study were to evaluate the pretreatment PSMA expression on immunohistochemistry (IHC) and PSMA uptake on PET/CT imaging in mCRPC patients who underwent PSMA-RLT. We correlated these parameters and a cell proliferation marker (Ki67) to the therapeutic efficacy of PSMA-RLT...
April 21, 2023: Clinical Genitourinary Cancer
Lucie-Marie Scailteux, Sébastien Vincendeau, Gwenaëlle Gravis, Romain Mathieu, Frédéric Balusson, Sandrine Kerbrat, Emmanuel Oger
PURPOSE: Using large French retrospective study cohort of chemotherapy-naïve metastatic castration-resistant prostate cancer patients (mCRPC; n = 10,308) comparing survival between patients who initiated abiraterone (ABI; 64%) and those initiating enzalutamide (ENZ; 36%), the present objective was to describe treatment patterns in the 2 years following initiation. METHOD: Using the national health data system (SNDS) from 2014 to 2018, we first explored the number of treatment lines, and secondly, patterns of patient management using state sequence analysis; cluster analyses were performed on the 0 to 12 month and 13 to 24 month periods...
April 20, 2023: Clinical Genitourinary Cancer
Lien-Ping Chou, Che-Wei Hsu, Sheau-Fang Yang, Chung-Ta Lee, Yin-Chien Ou, Kun-Che Lin, Che-Yuan Hu, Yeong-Chin Jou, Yuh-Shyan Tsai, Nan-Haw Chow
Introduction/Background To determine the clinical significance of micropapillary urothelial carcinoma (MPUC) of the upper urinary tract (UTUC) and a potential therapeutic strategy. Patients and Methods A retrospective cohort study was conducted to examine the incidence of micropapillary UTUC from 2010 to 2018 and its clinicopathological characteristics. Clinical outcomes and cancer-specific survival (CSS) were compared between MPUC and conventional UTUC matched by stage within a 6-month variation of receiving surgery...
April 20, 2023: Clinical Genitourinary Cancer
Benjamin N Schmeusser, Eric Midenberg, Arnold R Palacios, Adil A Ali, Dattatraya H Patil, Michelle Higgins, Reza Nabavizadeh, Benjamin Croll, Milton Williams, John Sheehy, Bill Zheng, Vikram M Narayan, Shreyas S Joshi, Kenneth Ogan, Sarah P Psutka, Mehmet A Bilen, Viraj A Master
BACKGROUND: Renal cell carcinoma (RCC) with tumor thrombosis often requires nephrectomy and tumor thrombectomy. As an extensive and potentially morbid operation, patient preoperative functional reserve and body composition is an important consideration. Sarcopenia is a risk factor for increased postoperative complications, systemic therapy toxicity, and death solid organ tumors, including RCC. The influence of sarcopenia in RCC patients with tumor thrombus is not well defined. This study evaluates the prognostic ability of sarcopenia regarding surgical outcomes and complications in patients undergoing surgery for RCC with tumor thrombus...
April 19, 2023: Clinical Genitourinary Cancer
Francesco Pierantoni, Michele Dionese, Umberto Basso, Eleonora Lai, Nicolò Cavasin, Elisa Erbetta, Alvise Mattana, Davide Bimbatti, Vittorina Zagonel, Sara Lonardi, Marco Maruzzo
INTRODUCTION: A low fT3/fT4 ratio has been associated with a poorer prognosis in patients treated for different solid malignancies. However, the prognostic role of baseline thyroid function in patients with metastatic urothelial carcinoma (mUC) has not yet been established. PATIENTS AND METHODS: We analyzed 72 consecutive immunotherapy-treated patients with mUC from a single institution. We recorded clinical data, baseline blood test results, and oncological outcomes...
April 18, 2023: Clinical Genitourinary Cancer
Elia Abou Chawareb, Christian H Ayoub, Adnan El-Achkar, Christelle Lattouf, Albert El-Hajj
INTRODUCTION: To assess the modified Global Leadership Initiative on Malnutrition (mGLIM) status as a predictor of postoperative mortality and morbidity in patients undergoing Radical Cystectomy (RC). METHODS AND MATERIALS: The American College of Surgeons - National Surgical Quality Improvement Program (ACS-NSQIP) dataset was used to select patients who underwent RC between the years 2011 to 2020. A positive mGLIM status includes patients with preoperative albumin levels < 3...
April 13, 2023: Clinical Genitourinary Cancer
Srivishnu Saravanabavan, Gagan J Prakash, Amit Joshi, Mahendra Pal, Ajit Gujela, Amandeep Arora, Ganesh Bakshi, Kumar Prabhash, Vanita Noronha, Vedang Murthy, Priyamvada Maitre, Ravi Teja
AIM: Optimal utilization of perioperative systemic therapy in locally advanced bladder cancer (LABC) holds the key in improving the survival outcomes. We aim to analyze the oncological outcomes of clinically locally advanced urothelial bladder cancer patients treated with neoadjuvant (NACT) or adjuvant chemotherapy or without any systemic therapy in the perioperative period of radical cystectomy. METHODS & MATERIAL: We retrospectively analyzed the medical records of patients with cancer of the urinary bladder diagnosed between 2012 and 2020...
April 11, 2023: Clinical Genitourinary Cancer
Yizhen Lai, Arielle G Bensimon, Emily Gao, Rituparna Bhattacharya, Ruifeng Xu, Jestinah Chevure, Kentaro Imai, Naomi B Haas
INTRODUCTION: Pembrolizumab was recently approved as an adjuvant treatment of renal cell carcinoma (RCC), based on prolonged disease-free survival compared to placebo in the phase III KEYNOTE-564 trial. The objective of this study was to evaluate the cost-effectiveness of pembrolizumab as monotherapy in the adjuvant treatment of RCC post-nephrectomy, from a US health sector perspective. PATIENTS AND METHODS: A Markov model with 4 health states (disease-free, locoregional recurrence, distant metastases, and death) was developed to compare the cost and effectiveness of pembrolizumab versus routine surveillance or sunitinib...
April 6, 2023: Clinical Genitourinary Cancer
Ting Xue, Zai-Shang Li, Chong Wu, Yong-Hong Li, Zhuo-Wei Liu, Zi-Ke Qin, Kai Yao, Fang-Jian Zhou, Hui Han
BACKGROUND: To investigate the value of the presurgical inflammatory biomarkers including C-reactive protein (CRP), albumin (ALB), C-reactive protein to albumin ratio (CAR), Glasgow prognostic score (GPS), the modified GPS (mGPS), and the high-sensitivity modified GPS (Hs-mGPS) in penile squamous cell carcinoma (PSCC) without distant metastasis and develop a tool to predict the overall survival (OS) of PSCC patients. METHODS: We retrospectively enrolled 271 PSCC patients without distant metastasis from 2006 to 2021...
April 5, 2023: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.